TÜrk neonatoloji derneğİ yeniDOĞan sariliklarinda yaklaşIM, İzlem ve tedavi rehberi 2014
Yüklə 1,06 Mb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- KAYNAKLAR 1.
|
34 – 37 8.5
11.5 13.5
1. Intrauterin dönemde etkilenmiş Rh uyuşmazlığı olan bebeklerde, doğum öncesinde 0 Rh (-‐) eritrosit suspansiyonu ve AB plazma + 0 (-‐) eritrosit hazırlatılır. Gerekirse doğum odasında kan değişimi yapılır. 2. Doğar doğmaz; yoğun fototerapi başlanır, IVIG verilir. 3. Kordondan hemoglobin ve bilirubin düzeyi gönderilir. 4. Hemoglobin, bilirubin düzeyi ve saatlik bilirubin düzeyi artış hızına göre kan değişimine karar verilir. 5. İlk 24 saatte çıkan sarılık her zaman patolojiktir. 6. İlk 24 saatte kan değişimi kararına bilirubin düzeyinin saatlik artış hızına göre karar verilir. 7. Yoğun FT’ye rağmen bilirubinin saatlik artış hızı 0.5 mg/kg/dl’nin üzerinde olan bebeklere kan değişimi uygulanır. 8. Endikasyonu olan bebeklerde IVIG uygulanır.
35
1. Hansen TWH, Bratlid D. Physiology of neonatal unconjugated hyperbilirubinemia. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of Jaundiced Neonate. New York: McGraw-‐Hill, 2012: 65-‐95. 2. Schwarz HP, Haberman BE, Ruddy RM. Hyperbilirubinemia. Current guidelines and emerging therapies. Pediatr Emer Care 2011; 27: 884-‐889. 3. Kaplan M, Muraca M, Hammerman C, et al. Inbalance between production and conjugation of bilirubin: a fundamental concept in the mechanism of neonatal jaundice. Pediatrics 2002; 110: e47. 4. Davidson L, Thilo EH. How to make kernicterus a "never event". Neoreviews 2003; 4:e308-‐e314. 5. Bhutani VK. Kernicterus as a “never event”: A newborn safety standart? Indian J Pediatr 2005; 72: 53-‐ 56.
6. Maisels MJ, Bhutani VK, Bogen D Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant ≥35 weeks gestation: an update with clarification. Pediatrics 2009; 124: 1193-‐1198. 7. American Academy of Pediatrics, Clinical Practice Guideline, Subcommittee on Hyperbilirubinemia. Management of the newborn 35 or more weeks of gestation. Pediatrics 2004; 114: 297-‐316. 8. Johnson L, Brown AK, Bhutani VK. BIND-‐a clinical score for bilirubin induced neurologic dysfunction in newborns. Pediatrics Suppl 1999; 104: 746-‐747. 9. Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin induced neurologic dysfunction (BIND). J Perinatol 2005; 25: 54-‐59. 10. Shapiro SM. Kernicterus. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of Jaundiced Neonate. New York: McGraw-‐Hill, 2012: 229-‐242. 11. Volpe JJ. Neurology of the Newborn, 4th Edition. Philadephia: WB Saunders, 2001. 12. Stevenson DK, Fanarof AA, Maisels MJ, et al. Prediction of hyperbilirubinemia in near-‐term and term infants. Pediatrics 2001; 108: 31-‐39. 13. American Academy of Pediatrics, Provisional Committee for Quality Improvement. Practice parameter: mamagement of hyperbilirubinemia in the healty term newborn. Pediatrics 1994; 94: 558-‐565. 14. Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot kernicterus registry (1992 to 2004). J Perinatol 2009; 29: 25-‐45. 15. Kaplan M, Merlob P, Regev R. Israel guidelines for the management of neonatal hyperbilirubinemia and prevention of kernicterus. J Perinatol 2008; 28: 389-‐397. 16. Bhutani VK, Johnson LH, Maisels JM, et al. Kernicterus: epidemiological strategies for its prevention through systems-‐based approaches. J Perinatol 2004; 24: 650–662. 17. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ 2006; 175: 587–590. 18. Govaert P, Lequin M, Swarte R, et al. Changes in globus pallidus with (pre)term kernicterus. Pediatrics 2003; 112: 1256–1263. 19. Ebbesen F, Andersson C, Verder H, et al. Extreme hyperbilirubinaemia in term and near-‐term infants in Denmark. Acta Paediatr 2005; 94: 59–64. 20. Bertini G, Dani C, Fonda C, Zorzi C, Rubaltelli FF. Bronze baby syndrome and the risk of kernicterus. Acta Paediatr 2005; 94: 968–971. 21. Manning D, Todd P, Maxwell M, Jane Platt M. Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed 2007; 92: F342–F346.
33: 451–453. 23. Bartmann P, Schaaf F. Kernicterus in Germany 2003–2005. Pediatric Academic Societies. Online abstract number: E-‐PAS2007:7936. 24. Watchko JF, Tribelli C. Bilirubin-‐induced neurologic damage-‐mechanisms and management approaches. N Engl J Med 2013; 369; 2021-‐2030. 36
hyperbilirubinemia. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of Jaundiced Neonate. New York : McGraw-‐Hill, 2012: 175-‐194. 26. Slusher TM, Olusaniya BO. Neonatal jaundice in low-‐and middle-‐income countries. In: Stevenson DK, Maisels MJ, Watchko JF, eds. Care of Jaundiced Neonate. New York : McGraw-‐Hill, 2012: 263-‐273. 27. Atkinson LR, Escobar GJ, Takayama J et al. Phototherapy use in jaundiced newborns in a large managed care organization:do clinicians adhere to the guideline? Pediatrics 2003; 111: e555–e561.
hyperbilirubinemia. Pediatrics 2004; 114:e130-‐153.
Güz 2002. 30. Bratlid D, Nakstad B, Hansen TWR. National guidelines for treatment of jaundice in the newborn. Acta Paediatrica 2011; 100: 499-‐505. 31. Barrington KJ, Sankaran K; Canadian Paediatric Society Fetus and Newborn Committee. Guidelines for detection, management and prevention of hyperbilirubinemia in term and pretem newborn infants. Paediatr Child Health 2007; 12(Suppl B): 1B-‐12B.
of jaundice newborn infants 35 0/7 or more weeks of gestation. Swiss Soc Neonatology 2007: 1–4. 33. Mishra S, Agarwal R, Deorari AK, Paul VK. Jaundice in the Newborn. AIIMS-‐NICU Protocols. 2007. www.newbornwkocc.org .
hyperbilirubinemia in preterm infants: background and synopsis of a national guideline. Early Hum Dev 2011, 87: 521–525.
and Management. 2009. www.health.gld.gov.au/qcg .
36. Newborn Service Clinical Guideline: Management of
Neonatal Jaundice. http://www.adhb.govt.nz/newborn/guidelines/GI/Jaundice.htm .
37. National Institute of Child
Health and
Clinical Excellence: 2011. http://pathways.nice.org.uk/pathways/neonatal-‐jaundice . 38. Atkinson M, Budge H. Review of the NICE guidance on neonatal jaundice. Arch Dis Child Educ Pract Ed 2011; 96: 136–140. 39. Romagnoli C,Barone G, Pratesi S, et al. Italian guidelines for management and treatment of hyperbilirubinemia of newborn infants >=35 weeks’ gestational age. Italian J Pediatr 2014; 40: 11. 40. Berns M, Bührer C. Leitlinie zur Hyperbilirubinaemie des Neugeborenen. Diagnostik und Therapie. Monatsschr Kinderheilkd 2010; 158; 1117-‐1124. 41. Kaplan M, Hammerman C. American Academy of Pediatrics guidelines for detecting neonatal hyperbilirubinaemia and preventing kernicterus. Arch Dis Child Fetal Neonatal Ed 2005; 90: F448– F449.
Genel Müdürlüğü, Devlet Planlama Teşkilatı ve Avrupa Birliği. Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü, Türkiye Nüfus ve
Sağlık Araştırması, 2008. Ankara-‐Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü: 2009. 43. Sarıcı SU, Serdar MA, Korkmaz A, et al. Incidence, course, and prediction of hyperbilirubinemia in near-‐ term and term newborns. Pediatrics 2004; 113: 775-‐780. 44. Tiker F, Gulcan H, Kilicdag H, Tarcan A, Gurakan B. Extreme hyperbilirubinemia in newborn infants. Clin Pediatr (Phila). 2006; 45: 257-‐261. 45. Katar S, Akay HO, Taskesen M, Devecioglu C. Clinical and cranial magnetic resonance imaging (MRI) findings of 21 patients with serious hyperbilirubinemia. J Child Neurol 2008; 23: 415-‐417. 37
Klinik Gelişim 2004; 17 (3/4): 47-‐55.
Ed 2011; 96: F461-‐F466. 48. De Carvalho M, Holl M, Harvey D. Effects of water supplementation on physiological jaundice in breast-‐fed babies. Arch Dis Child 1981; 56: 568–569. 49. Nicoll A, Ginsburg R, Tripp JH. Supplementary feeding and jaundice in newborns. Acta Paediatr Scand. 1982; 71: 759–761. 50. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-‐specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-‐term newborns. Pediatrics 1999; 103: 6–14.
42: 869-‐873. 52. Grohman K, Roser M, Rolinski B, et al. Pediatrics 2006; 117: 1174-‐1183. 53. Maisels MJ, Kring E. Transcutaneous bilirubin levels in first 96 hours in normal newborn population of>or =35 weeks gestation. Pediatrics 2006; 117: 169-‐173. 54. Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and photothrapy use. Pediatrics 2009; 124: 1031-‐1039. 55. Kuboi T, Kusaka T, Kawada K, et al. Hour-‐specific nomogram for transcutaneous bilirubin in Japanese neonates. Pediatr Int 2013; 55: 608-‐611. 56. Kaur S, Chawla D, Pathak U, Jain S. Predischarge non-‐invasive risk assesment for prediction of significant hyperbilirubinemia in term and late preterm neonates. J Perinatol 2012; 32: 716-‐721. 57. Türkmen M, Aydoğdu S, Gökbulut C, Çiğdem Yenisey, Ömer Söz, Çetinkaya-‐Çakmak B. Transcutaneous measurement of bilirubin in Turkish newborns: comparison with total serum bilirubin. Turk J Pediatr 2011; 53: 67-‐74.
Arch Dis Child Fetal Neonatal Ed 2009; 94: F317-‐F322. 60. Katar S, Devecioğlu C, Özel AK, Sucaklı İ. Kan Değişimi Yapılan Yenidoğan Bebeklerde Hiperbilüribinemi Etyolojisinin Değerlendirilmesi Dicle Tıp Dergisi 2006; 33: 174-‐177. 61. Maisels MJ. Jaundice. In Avery GB, Fletcher MA, MacDonald MG (eds). Neonatology: Pathophysiology and Management of the Newborn (5 th ed). Philadelphia: JB, Lippincott, 1999: 765-‐819. 62. Hannam S, McDonnell M, Rennie JM. Investigation of prolonged neonatal jaundice. Acta Paediatr 2000; 89: 694-‐697. 63. Wadsworth SJ, Suh B. In vitro displacement of bilirubin by antibiotics and 2-‐hydroxybenzoylglycine in newborns. Antimicrob Agents Chemother 1988; 32: 1571-‐1575. 64. Martin E, Fanconi S, Kälin P, et al. Ceftriaxone-‐-‐bilirubin-‐albumin interactions in the neonate: an in vivo study. Eur J Pediatr 1993; 152: 530-‐534. 65. Brodersen R, Ebbesen F. Bilirubin-‐displacing effect of ampicillin, indomethacin, chlorpromazine, gentamicin, and parabens in vitro and in newborn infants. J Pharm Sci 1983; 72: 248-‐253. 66. Gal P, Ransom JL, Davis SA. Possible Ibuprofen-‐induced kernicterus in a near-‐term infant with moderate hyperbilirubinemia. J Pediatr Pharmacol Ther 2006; 11: 245-‐250. 67. Amin SB, Harte T, Scholer L, Wang H. Intravenous lipid and bilirubin-‐albumin binding variables in premature infants. Pediatrics 2009; 124: 211-‐217. 68. Cashore WJ, Oh W, Brodersen R. Reserve albumin and bilirubin toxicity index in infant serum. Acta Paediatr Scand 1983; 72: 415–419. 69. Ebbesen F, Nyboe J. Postnatal changes in the ability of plasma albumin to bind bilirubin. Acta Paediatr Scand 1983;72:665–670. 70. Herschel M, Karrison T, Wen M, Caldarelli L, Baron B. Evaluation of the direct antiglobulin (Coombs’) test for identifying newborns at risk for hemolysis as determined by end-‐tidal carbon monoxide 38
concentration (ETCOc); and comparison of the Coombs’ test with ETCOc for detecting significant jaundice. J Perinatol 2002; 22: 341–347. 71. National Collaborating Centre for Women’s and Children’s Health. Neonatal Jaundice. London: NICE, 2010.
72. Bhutani VK; Committee on Fetus and Newborn; American Academy of Pediatrics. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2011; 128: e1046-‐1052.
about neonatal hyperbilirubinemia in 2011? J Matern Fetal Neonatal Med 2011; 24: 83-‐84. 74. Tan KL. The pattern of bilirubin response tophototherapy for neonatal hyperbilirubinaemia. Pediatr Res 1982; 16: 670–674. 75. Jährig K, Jährig D, Meisel P. Dependence of the efficiency of phototherapy on plasma bilirubin concentration. Acta Paediatr Scand 1982; 71: 293–299. 76. Hansen TW, Nietsch L, Norman E, et al. Reversibility of acute intermediate phase bilirubin encephalopathy. Acta Paediatr 2009; 98: 1689 –1694. 77. McDonagh AF, Agati G, Fusi F, Pratesi R. Quantum yields for laser photocyclization of bilirubin in the presence of human serum albumin: dependence of quantum yield on excitation wavelength. Photochem Photobiol 1989; 50(3): 305–319.
hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol 2012; 32: 660-‐ 664.
phototherapy. Acta Paediatr Taiwan 2002; 43: 255-‐258. 80. Shinwell ES, Sciaky Y, and Karplus M. Effect of position changing on bilirubin levels during phototherapy. J Perinatol 2002; 22: 226-‐9. 81. Mohammadzadeh A, Bostani Z, Jafarnejad F et al. Supine versus turning position on bilirubin level during phototherapy in healthy term jaundiced neonates. Saudi Med J 2004; 25: 2051-‐2. 82. Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current methods and future directions. Semin Perinatol 2004; 28: 326-‐33. 83. Garg AK, Prasad RS, Hifzi IA. A controlled trial of high-‐intensity double-‐surface phototherapy on a fluid bed versus conventional phototherapy in neonatal jaundice. Pediatrics. 1995; 95: 914–916. 84. Tan KL. Comparison of the efficacy of fiberoptic and conventional phototherapy for neonatal hyperbilirubinemia. J Pediatr 1994; 125: 607–612. 85. Schwartz HP, Haberman BE, Ruddy RM. Hyperbilirubinemia: current guidelines and emerging therapies. Pediatr Emer Care 2011; 27: 884-‐889.
know? What should we do? Eur J Pediatr 2011; 170: 1247-‐55.
covering the eyes on behavior of jaundiced infants treated with phototherapy. Biol Neonate. 1985; 47: 1– 8.
modified headbox and the conventional eyepatches. Ann Trop Paediatr 1997; 17: 349 –354. 89. Koç H, Altunhan H, Dilsiz A, et al. Testicularchanges in newborn rats exposed to phototherapy.Pediatr Dev Pathol. 1999; 2: 333–336. 90. Wurtman RJ. The effects of light on the human body. Sci Am 1975; 233: 69 –77. 91. Cetinkursun S, Demirbag S, Cincik M, Baykal B, Gunal A. Effects of phototherapy on newborn rat testicles. Arch Androl 2006; 52: 61–70. 92. Hooman N, Honarpisheh A. The effect of phototherapy on urinary calcium excretion in newborns. Pediatr Nephrol 2005; 20: 1363–1364. 39
27: 169–171.
Karamifar H, Pishva N. Prevalence of phototherapy induced hypocalcemia. Iran J Med Sci 2002; 27: 166–168.
95. Chen A, Du L, Xu Y et al. The effect of blue light exposure on the expression of circadian genes: bmal1 and cryptochrome 1 in peripheral blood mononuclear cells of jaundiced neonates. Pediatr Res 2005; 58: 1180–1184.
pictorial description of a rare condition. Arch Dis Child Fetal Neonatal Ed 2010; 95: F325. 97. Bertini G, Dani C, Fonda C et al. Bronze baby syndrome and the risk of kernicterus. Acta Paediatr 2005; 94: 968–971. 98. Lightner DA, Linnane WP, Ahlfors CE. Bilirubin photooxidation products in the urine of jaundiced neonates receiving phototherapy. Pediatr Res 1984; 18: 696–700. 99. Sisson TR. Photodegradation of riboflavin in neonates. Fed Proc. 1987; 46: 1883–1885. 100. Horacio S. Falciglia and Corryn S. Double Volume Exchange Transfusion: A Review of the ''Ins and Outs''. Neoreviews 2013; 14; e513. 101. MacDonald MG, Ramasethu J. Atlas of procedures in neonatology. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Business, 2007. 102. Sharafi R, Mortazavi Z, Sharafi S, Parashkouh RM. The effect of clofibrate on decreasing serum bilirubin in healthy term neonates under home phototherapy. Iran J Pediatr 2010; 20: 48-‐52. 103. Dennery PA. Pharmacological interventions for the treatment of neonatal jaundice. Semin Neonatol 2002; 7: 111-‐119. 104. Caglayan S, Candemir H, Aksit S, Kansoy S, Asik S, Yaprak I. Superiority of oral agar and phototherapy combination in the treatment of neonatal hyperbilirubinemia. Pediatrics 1993; 92: 86-‐89. 105. Stevenson DK, Wong RJ. Metalloporphyrins in the management of neonatal hyperbilirubinemia. Semin Fetal Neonatal Med 2010; 15: 164–168.
Watchko JF, eds. Care of Jaundiced Neonate. New York: McGraw-‐Hill, 2012. Yüklə 1,06 Mb. Dostları ilə paylaş:
|